Since Novo Nordisk was founded more than 90 years ago, we have been driving change to defeat diabetes. Novo Nordisk is using its knowledge of protein chemistry, understanding of hormones and disease insight to develop treatments for people with obesity.
Obesity can have many serious health consequences, including type 2 diabetes, heart disease, high blood pressure, obstructive sleep apnoea and many types of cancer.
Novo Nordisk are committed to addressing the significant unmet
medical needs in obesity care and our ambition is to drive scientific
progress in this disease area and develop treatment options for
Reviewed: October 2019